Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study

Autor:	Ying Cheng, Yan Wang, Jun Zhao, Yunpeng Liu, Hongjun Gao, Kewei Ma, Shucai Zhang, Hua Xin, Jiwei Liu, Chengbo Han, Zhitu Zhu, Jun Chen, Fugang Wen, Junling Li, Jie Zhang, Zhendong Zheng, Zhaoxia Dai, Hongmei Piao, Xiaoling Li, Yinyin Li, Min Zhong, Rui Ma, Yongzhi Zhuang, Yuqing Xu, Zhuohui Qu, Haibo Yang, Chunxia Pan, Fan Yang, Daxin Zhang, Bing Li
Rok vydání:	2018
Předmět:	0301 basic medicine Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty medicine.drug_class medicine.medical_treatment Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy Medicine In patient Epidermal growth factor receptor Lung cancer Lymph node Chemotherapy biology medicine.diagnostic_test business.industry General Medicine medicine.disease respiratory tract diseases 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis biology.protein Adenocarcinoma business
Zdroj:	Thoracic Cancer. 9:1461-1469
ISSN:	1759-7706
DOI:	10.1111/1759-7714.12859
Popis:	BACKGROUND Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non-small cell lung cancer (NSCLC), EGFR mutation testing is required. However, few studies have evaluated the extent of EGFR testing in real-world practice in China. METHODS A multicenter, observational study of EGFR testing in NSCLC patients in North China was conducted. Treatment-naive patients or those with postoperative recurrent stage IIIB/IV NSCLC were enrolled. The primary objective was EGFR testing rate. Secondary objectives included EGFR mutation status, EGFR testing methods and specimens, factors associated with EGFR testing, and overall survival with or without EGFR testing. RESULTS Overall, 2809 patients with stage IIIB/IV NSCLC were enrolled; 90.78% had adenocarcinoma. The EGFR screening rate was 42.54%. EGFR testing rates were higher in tumor samples obtained by lymph node puncture, and in patients with urban medical insurance, adenocarcinoma, non-smokers, or those located in developed cities (all P < 0.001). The EGFR mutation rate was 46.44%. The most commonly used specimens for EGFR testing were biopsy tumor samples (67.53%). PCR-based methods (72.05%), Sanger sequencing (5.36%), and Luminex liquid chip (5.10%) were the most frequently used testing platforms. Similar positive EGFR mutation rates were achieved with different platforms. TKI therapy was the first-line treatment administered to most EGFR-positive patients (56.22%), and chemotherapy in EGFR-negative patients (84.88%). Overall survival was higher in EGFR-tested than in untested patients (27.50 vs. 19.73 months; P = 0.007). CONCLUSION Real-world EGFR testing rates for NSCLC in North China were relatively low because of clinical and social factors, including medical insurance coverage.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::96f4b338189c04e0a5473cd4f3c12a9f https://doi.org/10.1111/1759-7714.12859 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.